Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial
| العنوان: | Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial |
|---|---|
| المؤلفون: | Ha-Young Na, Yong Kyu Lee, Sang-Ho Lee, Ju-Young Moon, Jeong-Hae Kie, Sang-Woong Han, Hoon Young Choi, Young-Il Jo, So-Dug Lim, Dong-Ho Yang, Hyeong Cheon Park, Sug-Kyun Shin |
| المصدر: | The Korean Journal of Internal Medicine |
| بيانات النشر: | The Korean Association of Internal Medicine, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Time Factors, 030232 urology & nephrology, Urology, Renal function, Blood Pressure, 030204 cardiovascular system & hematology, urologic and male genital diseases, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Republic of Korea, medicine, Humans, Prospective Studies, Prospective cohort study, Creatinine, Proteinuria, business.industry, Glomerulonephritis, IGA, Middle Aged, medicine.disease, Blood pressure, Endocrinology, Treatment Outcome, Valsartan, chemistry, Tolerability, Nephrology, Original Article, Female, medicine.symptom, Safety, business, Angiotensin II Type 1 Receptor Blockers, Progressive disease, Biomarkers, medicine.drug, Angiotensin receptor antagonists |
| الوصف: | Background/Aims: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in patients with favorable prognostic features. In this study, we aimed to investigate the antiproteinuric effect and tolerability of low-dose valsartan (an angiotensin II receptor blocker) therapy in normotensive IgAN patients with minimal proteinuria of less than 0.5 to 1.0 g/day. Methods: Normotensive IgAN patients, who had persistent proteinuria with a spot urine protein-to-creatinine ratio of 0.3 to 1.0 mg/mg creatinine, were recruited from five hospitals and randomly assigned to either 40 mg of valsartan as the low-dose group or 80 mg of valsartan as the regular-dose group. Clinical and laboratory data were collected at baseline, and at 4, 8, 12, and 24 weeks after valsartan therapy. Results: Forty-three patients (low-dose group, n = 23; regular-dose group, n = 20) were enrolled in the study. Proteinuria decreased significantly not only in the regular-dose group but also in the low-dose group. The change in urine protein-to-creatinine ratio at week 24 was −41.3% ± 26.1% (p < 0.001) in the regular-dose group and −21.1% ± 45.1% (p = 0.005) in the low-dose group. In the low-dose group, blood pressure was constant throughout the study period, and there was no symptomatic hypotension. In the regular-dose group, blood pressure decreased at weeks 8 and 12. No significant change in glomerular filtration rate, serum creatinine level, or serum potassium level was observed during the study period. Conclusions: Our results suggest that low-dose valsartan can significantly reduce proteinuria without causing any intolerability in normotensive IgAN patients with minimal proteinuria. |
| اللغة: | English |
| تدمد: | 2005-6648 1226-3303 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ab3c52e9a394a671523636b0c4d6564Test http://europepmc.org/articles/PMC4773712Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7ab3c52e9a394a671523636b0c4d6564 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20056648 12263303 |
|---|